A Phase 2 interventional study of Placebo and NVA237 in Chronic Obstructive Pulmonary Disease, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-09-14.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 61st largest by enrollment, is one of 4 that started in 2009, is one of 19 in phase 2, and was the 6th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 98th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2009, is one of 21 in phase 2, and was the 33rd registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
Drug: Placebo · Drug: NVA237
NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
Drug: Placebo · Drug: NVA237
Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from predose (day 1) to the readings taken 0-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
Time frame: From Day 1 to 0-24 hours after drug administration on Day 14
Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 0-12 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
Time frame: From day 1 to 0 -12 hours after drug administration on Day 14
Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 12-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
Time frame: From Day 1 to 12 hours-24 hours after drug administration on Day 14
Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs)
According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening , causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. See Adverse Events module for details.
Time frame: Day 14
| Milestone | NVA237 50μg Then Placebo | Placebo Then NVA237 50μg |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 17 |
| Not completed | 0 | 0 |
| Milestone | NVA237 50μg Then Placebo | Placebo Then NVA237 50μg |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 15 |
| Not completed | 0 | 2 |
| Withdrew: Abnormal test procedure results | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from predose (day 1) to the readings taken 0-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
| Liters | NVA237 50μg | Placebo |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14 | 1.827 ± 0.0330 | 1.664 ± 0.0324 |
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 0-12 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
| Liters | NVA237 50μg | Placebo |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) AUC 0-12 Hours on Day 14 | 1.879 ± 0.0346 | 1.714 ± 0.0340 |
Forced Expiratory Volume in one second (FEV1) was calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. This outcome measures the change is FEV1 from pre-dose (day 1) to the readings taken 12-24 hours post dose on day 14. The variable was analyzed with an analysis-of-covariance model which included baseline FEV1 value as a covariate.
| Liters | NVA237 50μg | Placebo |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) AUC 12-24 Hours on Day 14 | 1.776 ± 0.0344 | 1.615 ± 0.0339 |
According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening , causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. See Adverse Events module for details.
| Participants | NVA237 50μg | Placebo |
|---|---|---|
| Overall Adverse Events | 2 | 4 |
| Serious Adverse Events (SAEs) | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/33 (0%) | 2/33 (6.1%) |
| NVA237 50 μg | — | 0/31 (0%) | 0/31 (0%) |
| Event | Placebo | NVA237 50 μg |
|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 2/33 | 0/31 |
| Age, Continuous(years) | All Randomized Patients |
|---|---|
| Mean | 60.5 ± 9.13 |
| Sex: Female, Male(Participants) | All Randomized Patients |
|---|---|
| Female | 11 |
| Male | 22 |
The record gives a start of Feb 2009, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →